Genetic features of platinum-resistant ovarian cancer patients

• 作 者: V.G.Dubinina A.I.Rybin M.A.Lysenko
• 机 构: Odessa National Medical University,
• 出 处: 中国现代医学杂志
• 发表日期: 2014年15期
• 关键词: ovarian cancer treatment resistance to platinum mutation of genes BRCA 1 BRCA 2

The authors try to decide a problem of ovarian cancer resistance to platinum drugs by the way of correlation finding between platinum-resistance of tumor and presence of gene mutations in the patient.It was shown a variety of options for BRCA gene mutations in patients with ovarian cancer:BRCA 1(185delAG)-64.2%,BRCA 1(5382 insC)-55.7%,and BRCA 2(6174delT)-53.8%.Authors discovered a significant positive correlation between carriage of mutations in the BRCA genes 1/2 and the sensitivity of malignant ovarian tumors to chemotherapy with platinum.Mutations in these genes occurred significantly more often in patients with platinum-sensitive ovarian cancer.

The authors try to decide a problem of ovarian cancer resistance to platinum drugs by the way of correlation finding between platinum-resistance of tumor and presence of gene mutations in the patient. It was shown a variety of options for BRCA gene mutations in patients with ovarian cancer: BRCA 1 (185delAG) -64.2%, BRCA 1 (5382 insC) -55.7%, and BRCA 2 (6174delT) -53.8% .Authors discovered a significant positive correlation between carriage of mutations in the BRCA genes 1/2 and the sensitivity of malignant ovarian tumors to chemotherapy with platinum. Mutations in these genes occurred significantly more often in patients with platinum-sensitive ovarian cancer.